Hennessy BT - Search Results

1

Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer.

Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Gonzalez-Angulo AM, et al. Among authors: hennessy bt. Clin Proteomics. 2011 Jul 8;8(1):11. doi: 10.1186/1559-0275-8-11. Clin Proteomics. 2011. PMID: 21906370 Free PMC article.

2

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.

Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Hennessy BT, et al. Ann Oncol. 2005 Aug;16(8):1289-96. doi: 10.1093/annonc/mdi253. Epub 2005 May 12. Ann Oncol. 2005. PMID: 15890665 Free article. Review.

3

Adjuvant therapy for breast cancer.

Hennessy BT, Pusztai L. Hennessy BT, et al. Minerva Ginecol. 2005 Jun;57(3):305-26. Minerva Ginecol. 2005. PMID: 16166938 Review.

4

Squamous cell carcinoma of the breast.

Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V, Hortobagyi GN. Hennessy BT, et al. J Clin Oncol. 2005 Nov 1;23(31):7827-35. doi: 10.1200/JCO.2004.00.9589. J Clin Oncol. 2005. PMID: 16258085

5

Exploiting the PI3K/AKT pathway for cancer drug discovery.

Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Hennessy BT, et al. Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. doi: 10.1038/nrd1902. Nat Rev Drug Discov. 2005. PMID: 16341064 Review.

6

Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.

Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN. Hennessy BT, et al. Nat Clin Pract Oncol. 2005 Dec;2(12):598-9. doi: 10.1038/ncponc0375. Nat Clin Pract Oncol. 2005. PMID: 16341096 No abstract available.

7

Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.

Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Hennessy BT, et al. J Clin Oncol. 2005 Dec 20;23(36):9304-11. doi: 10.1200/JCO.2005.02.5023. J Clin Oncol. 2005. PMID: 16361629

8

Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer.

Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Hennessy BT, et al. Eur J Hum Genet. 2006 Apr;14(4):381-3. doi: 10.1038/sj.ejhg.5201570. Eur J Hum Genet. 2006. PMID: 16418735 No abstract available.

9

Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.

Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Hennessy BT, et al. Cancer. 2006 Mar 1;106(5):1000-6. doi: 10.1002/cncr.21726. Cancer. 2006. PMID: 16444747 Free article. Clinical Trial.

10

Biphasic metaplastic sarcomatoid carcinoma of the breast.

Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, Babiera G, Hortobagyi GN, Valero V. Hennessy BT, et al. Ann Oncol. 2006 Apr;17(4):605-13. doi: 10.1093/annonc/mdl006. Epub 2006 Feb 9. Ann Oncol. 2006. PMID: 16469754 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

207 results

Search Page